Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

2024.09.03
The CHRYSALIS-2 study (NCT04077463) Cohort C investigated the combination of amivantamab and lazertinib for the treatment of patients with atypical EGFR-mutant non-small cell lung cancer (NSCLC). The study enrolled patients with various EGFR mutations who were either treatment-naive or had received limited prior treatment. The results demonstrated that the amivantamab+lazertinib combination showed promising antitumor activity, particularly in treatment-naive patients. The overall response rate was 51% (95% CI: 41%-61%), with a response rate of 55% (95% CI: 40%-69%) in treatment-naive patients. In this subgroup, the median progression-free survival (PFS) for the amivantamab+lazertinib combination was 19.5 months (95% CI: 11.0-not estimable). Overall, these findings suggest that amivantamab+lazertinib has potential as a new treatment option for patients with advanced NSCLC carrying atypical EGFR mutations. Principal investigator Dr. Byoung Chul Cho from Yonsei Cancer Center in Korea discussed the results of this study in an international media interview.
International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

2024.09.03
In 2022, Dr. Chunxue Bai from Fudan University Shanghai Cancer Center, introduced the concept of "Metaverse Medicine," aiming to leverage metaverse technology to revolutionize disease prevention and treatment. At the 2024 International Lung Cancer Academic Conference, Professor Bai presented a report titled "Lung Cancer Screening and Management in the Metaverse Era." This article provides a summary of the main points of his report.
Balancing Standardization and Innovation: Dr. Jin Li Shares Conference Highlights and the Future of AI in Clinical Research

Balancing Standardization and Innovation: Dr. Jin Li Shares Conference Highlights and the Future of AI in Clinical Research

2024.09.03
The "2024 CSCO Digestive Tract Tumor Standardized Treatment Workshop," co-hosted by the Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation, and Hangzhou Oriental Clinical Oncology Research Center, was held in Shanghai from August 17-18, 2024. This workshop featured diverse learning methods, including lectures, discussions, and live surgical demonstrations, aimed at improving the standardized treatment of digestive tract tumors, reducing regional disparities, and disseminating new advancements and concepts. Oncology Frontier interviewed Dr. Jin Li, President of Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Chairman of the CSCO Foundation, and Chairman of the CSCO Gastric Cancer Expert Committee, to discuss the highlights and significance of this workshop, as well as the potential and future of artificial intelligence in clinical research.
In-Depth Analysis of UTUC MDT Diagnosis, Radiotherapy, and Translational Development, Pioneering the Path Forward with CUDA-UTUC

In-Depth Analysis of UTUC MDT Diagnosis, Radiotherapy, and Translational Development, Pioneering the Path Forward with CUDA-UTUC

2024.09.03
From August 8 to 11, 2024, the Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital as the organizer and the Shaanxi Provincial Medical Association Urological Surgeons Branch as a co-organizer. Under the theme of "Healthy China, Urology First," the conference gathered many of the latest achievements in urology. At the event, Urology Frontier invited Dr. Xuesong Li, Dr. Qi Tang, and Dr. Xiaoying Li from Peking University First Hospital for an in-depth discussion on the current state of non-invasive detection, radiotherapy, and translational medicine for upper tract urothelial carcinoma (UTUC). They also shared their experiences in building subspecialties for UTUC and outlined the direction in which CUDA-UTUC is leading the field.
2024 CUDA丨Dr. Guohua Zeng: China’s Leading Role in Minimally Invasive Urological Stone Surgery, Enhancing Patient Quality of Life

2024 CUDA丨Dr. Guohua Zeng: China’s Leading Role in Minimally Invasive Urological Stone Surgery, Enhancing Patient Quality of Life

2024.08.31
The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an from August 8 to 11, 2024. The conference, organized by the Chinese Medical Association and the CUDA Urological Surgeons Branch, was hosted by the Air Force Medical University Xijing Hospital and co-organized by the Shaanxi Provincial Medical Association Urological Surgeons Branch. The event showcased the latest achievements in urology from a broad and diverse perspective. During the conference, Urology Frontier interviewed the Honorary Chairman of the conference, Dr. Guohua Zeng from The First Affiliated Hospital of Guangzhou Medical University, who shared insights on the remarkable achievements of minimally invasive urological stone surgery in China, the development trends of percutaneous nephrolithotomy (PCNL), and valuable suggestions for improving the treatment and quality of life for patients with urinary stones.
Dr. Hailiang Zhang: Analyzing the Characteristics of Chinese UTUC Patients and Exploring Targeted Treatment Strategies to Meet the Needs of More UTUC

Dr. Hailiang Zhang: Analyzing the Characteristics of Chinese UTUC Patients and Exploring Targeted Treatment Strategies to Meet the Needs of More UTUC

2024.08.31
Upper tract urothelial carcinoma (UTUC), which includes renal pelvis cancer and ureteral cancer, is classified alongside bladder cancer as a type of urothelial carcinoma. However, the overall incidence of UTUC is relatively low, and there are still some contentious issues in its diagnosis and treatment strategies. At the recent 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association held in Xi'an, Dr. Hailiang Zhang from Fudan University Shanghai Cancer Center delivered an insightful lecture titled "Systemic Treatment of UTUC: Challenges, Breakthroughs, and Future Directions." Following the conference, Urology Frontier invited Professor Zhang to discuss the characteristics of UTUC patients in China, perioperative treatment strategies, and the progress of his research team.